[Effects and action mechanisms of macrolides on IgG- immune complex lung injury models].
Tamaoki
A
A
Kori
K
K
Kondo
M
M
Tagaya
E
E
Isono
K
K
Aoshiba
K
K
Nagai
A
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use; D007105:Immune Complex Diseases / Q000188:drug therapy* / Q000378:metabolism; D007074:Immunoglobulin G; D015570:Josamycin / Q000494:pharmacology / Q000627:therapeutic use; D008171:Lung Diseases / Q000188:drug therapy* / Q000378:metabolism; D016676:Macrophages, Alveolar / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D000900:Anti-Bacterial Agents; D016207:Cytokines; D007074:Immunoglobulin G; D009569:Nitric Oxide; D004917:Erythromycin; D015570:Josamycin